1. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Issue 1 (13th October 2009) Authors: Straumann, A; Conus, S; Grzonka, P; Kita, H; Kephart, G; Bussmann, C; Beglinger, C; Smith, D A; Patel, J; Byrne, M; Simon, H-U Journal: Gut Issue: Volume 59:Issue 1(2010) Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P192 Extreme body mass indices are frequent in inflammatory bowel disease patients and are associated with higher disease activity in Crohn`s disease, but not in ulcerative colitis: a cross-sectional analysis of the Swiss IBD cohort study. (16th January 2018) Authors: Greuter, T; Porchet, F; Fournier, N; Biedermann, L; Schreiner, P; Scharl, M; Schoepfer, A; Safroneeva, E; Straumann, A; Rogler, G; Vavricka, S Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗